

Yale Eye Center Grand Rounds

“Surgical Considerations for Subretinal Gene Therapy Delivery”

Friday, July 31, 2020

7:00 am – 8:15 am

Zoom

Meeting ID: 923 8830 4701

Course Director:

Ron A. Adelman, MD, MPH, MBA



Andreas K. Lauer, MD

Chair, Dept of Ophthalmology
Thiele-Petti Endowed Chair and
Professor

Chief, Vitreoretinal Division
Casey Eye Institute - Oregon
Health & Science University

There is no corporate support for this activity.

This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Eye care professionals.

NEEDS ASSESSMENT

Ocular Gene Therapy is an emerging field that is beginning to allow ophthalmologists to treat conditions that previously caused irreversible blindness. Presently, there is one approved gene therapy treatment and numerous other treatments are likely to become available in the coming

years. To date little has been described to enhance the surgical technique to handle fragile retinal tissue while administering treatment. The intent of the presentation is to describe intraoperative features that will help refine surgical technique in ocular gene therapy surgery.

LEARNING OBJECTIVES

At the conclusion of the conference, meeting participants will be able to:

- Understand for which the conditions gene therapy are investigational or FDA approved.
- Describe intraoperative findings in gene therapy surgery.
- Understand surgical considerations during gene therapy surgery.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1.5 AMA PRA Category 1 Credit(s)™.

Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker: Andreas K. Lauer, MD – Alcon, Allergan, Applied Genetic Technologies Corp., Editas/Allergan, Genentech, Gyroscope, Invericbio, Nightstar/Biogen, Sanofi, Oxford BioMedica – Research Support. Applied Genetic Technologies Corp., Invericbio, Nightstar/Biogen, REGENXBIO – Consulting Fee.
Course Director: Ron A. Adelman, MD, MPH, MBA – NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

